The role of probiotics in digestive health

Arthur C Ouwehand
Active Nutrition, DuPont Nutrition and Health, Kantvik, Finland

Abstract: Although probiotics have documented health benefits outside the gastrointestinal tract, digestive health remains the key benefit for probiotics. Advances in technology have made even more in-depth analyses of the intestinal microbiota possible. Nevertheless, a healthy microbiota cannot be defined due to individual differences and changes with age. Probiotics, in general, will not cure or prevent disease, but will aim at maintaining health and reducing risk for disease; although probiotic pharmaceuticals are possible. Meta-analyses have indicated several areas where probiotics can exert health benefits such as certain types of diarrhea, constipation, and inflammatory diseases of the intestine. There is also an ever-increasing understanding of the mechanisms of probiotic action. However, it remains challenging to pinpoint specific strain combinations for explicit health benefits. The increased understanding of the intestinal microbiota composition and activity will make it likely that in the future we will see new probiotics from genera other than Lactobacillus, Bifidobacterium, or Saccharomyces; these may focus on new or existing health targets.

Keywords: Lactobacillus, Bifidobacterium, intestinal microbiota, health, novel probiotics

Introduction
The most widely accepted definition for probiotics is the one proposed by the Food and Agriculture Organization/World Health Organization working group and recently reaffirmed by the International Scientific Association for Probiotics and Prebiotics: live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. The definition thus highlights three major points: 1) the viability of the microbes, 2) the dose, and 3) the documented health benefit.

Viability
The viability of the microbes sets certain technological challenges. Most probiotics belong to the genera Lactobacillus and Bifidobacterium, although strains and species from other genera are also being used. This requires that the microbes remain viable until the end of shelf life. Probiotics are commonly consumed in two main formats: as a food and as a dietary supplement. Foods, in general, have a high water activity and the fermented foods have a low pH. Such foods will often require refrigerated storage and have a limited shelf life; weeks rather than months or years. In the case of dietary supplements, the water activity is usually low, but the products tend to be stored at ambient temperatures and may have shelf lives of up to 2 years. Until the end of shelf life, a sufficient dose needs to be available. Preferably, this is mentioned on the product; the amount of viable microbes at time of manufacture is of less interest.
as it does not indicate what the minimal dose is at time of consumption.

**Dose**

Dose is thus important. However, what this dose should be is not always that clear. A rule of thumb is that the dose should be at least $10^9$ colony-forming units, although Health Canada recommends at least $10^7$ colony-forming units for a general probiotic claim. However, the dose is likely to be dependent on the particular probiotic strain (combination), the health benefit, and subpopulation the consumer belongs to. Therefore, the dose that has been documented to provide a health benefit should be taken as per the guidelines; as is also required by Health Canada for specific health claims.

**Health benefit**

Finally, there is the health benefit; what constitutes a health benefit and what not? At the time of writing (October 2015), the European Food Safety Authority did not approve health claims for probiotics. This should, however, not be interpreted in a way that probiotics do not provide health benefits. An in-depth analysis of the regulatory challenges of probiotic health claims in various jurisdictions falls outside the scope of this work. For simplicity, here, a health benefit will be interpreted as an improvement in a clinical outcome. This means that changes in the microbiota composition or certain immune markers will not be considered. The strength of such markers is not generally accepted.

**Safety**

Although not mentioned in the definition, it is obvious that probiotics are commercialized should be well identified and safe. Identification should be done by molecular techniques. Although not required, genome sequencing is nowadays so cost-effective that it would not be excessive to request for commercial probiotic strains. For members of the genera *Bifidobacterium* and *Lactobacillus*, safety is not an issue for the general population. For consumers (patients) with a poor general health and in particular a poor immune status, a risk–benefit consideration should be made. This population tends to have the greatest potential benefit from probiotics, and risk (usually infection) remains small. In the unlikely event an infection should happen, it can be easily treated. Finally, for the benefit of all consumers, commercialized probiotics should not harbor transferable antibiotic resistance. This is something that can be tested both phenotypically and through genome analysis.

**Strain specificity versus commonality**

Most commercial probiotics belonging to the narrow group of lactic acid bacteria, lactobacilli and bifidobacteria, have been isolated from similar sources like fermented dairy products or intestine, and have generally been selected to survive low pH and bile acids. It is therefore reasonable to assume that different strains share some properties, while other characteristics may indeed be specific for a particular strain; this is schematically represented in Figure 1.

**Intestinal microbiota**

Techniques to analyze the intestinal microbiota composition and activity are continuously improving; enabling analyses that were until recently considered impossible. An in-depth review of the intestinal microbial analyses falls outside the scope of this work and the reader is referred to other sources for this, for example, Lankelma et al. However, there is general agreement that the intestinal microbiota, which by the way is the correct term for what used to be referred to as the intestinal microflora (we are dealing with small life, not small plants), plays a major role in health and disease and in much more areas than previously thought. Intestinal microbiota often refers to fecal microbiota, therefore, it is important to realize that different parts of the gastrointestinal tract harbor different microbiota.

Despite developments in analytical techniques, it has been difficult to pinpoint specific organisms or groups of organisms that are causally associated with certain health conditions. This is one of the reasons why changing the composition of the microbiota is often not considered a health benefit as it is not clear what change is desired; not even increasing levels of bifidobacteria and/or lactobacilli. One thing, however, becomes clear; in general, diversity is good. Many disease conditions appear to be associated with a...
reduced microbial diversity. This is not a surprise; in ecology, diversity in an ecosystem is associated with resilience and monocultures are susceptible to disturbances.

Although there is a general agreement that the intestinal microbiota plays a prominent role in health and disease, the exact mechanisms and contributions by the various members are still only poorly understood. This is also complicated by the fact that every individual has his or her own personal microbiota; there is no “standard” healthy microbiota as it would be different for everyone and changes during our life.8

Some probiotics have been shown to change the composition of the intestinal microbiota. This does, however, not always happen.8 A reason for this could be that a healthy microbiota, whatever it is, is able to resist changes induced by outside factors; both good (probiotics) and bad (pathogens). When a microbiota is disturbed, probiotics may help in its recovery, that is, returning to its original state.10 A clear example of this is in association with antibiotic use (see Antibiotic-associated diarrhea section). While most commercial probiotics have been documented to survive gastrointestinal transit, this in itself is not a health benefit and also does not explain how they can contribute to microbiota recovery as probiotics are not simply supplementing depleted species. Rather probiotics appear to be contributing to an improvement in the local environment that allows the microbiota to recover.

**Digestive health**

Digestive health is not formally defined. In practice, it should be defined through the absence of intestinal complaints. This is clearly not satisfying, but may work from a practical perspective. Most healthy consumers will be happy with their digestive health if they are not having any symptoms, that is, are not reminded of their intestines in the first place.

Therefore, digestive health therefore focuses on reducing risk for gastrointestinal disturbances and/or relieving such symptoms if and when they occur. This is discussed in the next section.

Although probiotics can be used as a drug, most probiotics are marketed as food ingredients or as dietary supplements.1 As such, probiotics are not expected to prevent disease, they may reduce the risk of disease. Probiotics do not treat or mitigate disease, they may relieve symptoms of disease. Therefore, most probiotics are not treated as drug, their main aim is to maintain health. Furthermore, traditional fermented foods such as yogurt, sauerkraut, and kimchi are not probiotics, unless they contain specific strains with documented health benefits such as certain probiotic yogurts (Figure 2).

**Constipation, slow intestinal transit**

Constipation is one of the most common digestive disorders. Although benign, constipation has a substantial influence on general well-being and is considered as a risk for certain serious intestinal conditions such as diverticulitis. Constipation is defined as three or less spontaneous bowel movements per week. It is more common in females than in males and tends to increase with age. Even though clearly defined, constipation is to some extent subjective and difficult to measure. Alternative measures are the Bristol Stool Scale11 and intestinal transit time. Intestinal transit time can be measured with various techniques, using dyes such as carmine red, radiopaque markers, and so-called smart pills. The former determines oroanal transit time and is not very sensitive as subjects tend to defecate once a day or less.12 Radiopaque markers are sensitive, but require that subjects are compliant with their consumption of the markers for 6 days (to create a steady state) and involves exposure to radiation.13 The so-called smart pill provides more information than just colonic transit time;14 the technique is, however, expensive and has not been routinely used for measuring transit for research purposes. Most probiotic studies on intestinal transit have therefore used radiopaque markers and abdominal X-ray.

A number of probiotics have been tested for their effect on slow intestinal transit; most of them are *Bifidobacterium lactis* strains, such as *B. lactis* DN-173010, *B. lactis* HN019, or the combination of *Bifidobacterium longum* BB536 and *B. lactis* 420.15 In general, the tested probiotics have been found to shorten colonic transit.16,17 Important here is that the probiotics do not shorten the transit time of subjects with “normal” initial transit times, that is, they do not cause diarrhea (Figure 3). Probiotics have also been shown to improve stool frequency and consistency.18 Although studies have used many different doses, meta-analyses have failed to observe a dose–response effect.17

**Antibiotic-associated diarrhea**

Antibiotic-associated diarrhea (AAD) has been reported to occur between 5% and 39% of patients on antibiotics.19 However, the source data for these numbers is relatively old and focuses on hospitalized patients. A more recent
Many more probiotic strains and combinations have been shown to be efficacious and it is beyond the scope of this review to describe them all. For further details the reader is referred to the study by Hempel et al.20

Interestingly, in AAD, two rare probiotic dose–response studies have been performed.24,25 Both studies find that the higher dose was more efficacious than the lower tested dose. Although this should not be generalized, it is interesting to note that dose–response effects have been observed with probiotics.

**Community-acquired diarrhea**

Community-acquired diarrhea can be caused by a multitude of pathogens, toxins, and other factors. Some of the best investigated community-acquired diarrhea targets for probiotics are rotavirus diarrhea and traveler’s diarrhea.

*L. rhamnosus* GG is an example of a probiotic that has been shown to reduce the risk for rotavirus diarrhea in children in a hospital setting (ie, a nosocomial infection)28 and has also been observed to aid in the treatment of rotavirus diarrhea.29 For reducing the risk of rotavirus infection in day care centers, the evidence is minimal to modest30 for all strains tested. With the availability of a rotavirus vaccine, it is uncertain to what extent this is still a relevant target, both in hospital and community settings. In community-acquired diarrhea, the etiology is often not determined, but also with these diarrheas, probiotics such as *B. lactis* HNO19,31,32 or *L. paracasei* Lpc-3733 have been observed to be successful in reducing risk, especially in young children.

Traveler’s diarrhea has a plethora of causes; it is therefore not surprising that probiotics are less successful in preventing this type of diarrhea, with an estimated (nonsignificant) reduction of 8%.34 In addition to this, the studies that have been used in evaluating the efficacy suffer from high attrition rates.

However, where efficacious, the use of probiotics has been calculated to reduce cost for diarrhea treatment by 25%. While initial cost was increased (cost for the probiotic), subsequent additional medication and consultations were reduced.22

It may seem contradictory that a probiotic can both reduce transit time in the case of constipation and prolong it in the case of diarrhea. However, a more correct perspective is that probiotics normalize the transit time (Figure 3).35

**Irritable bowel syndrome**

Irritable bowel syndrome (IBS), not to be confused with inflammatory bowel disease (IBD), is not a disease but a syndrome. IBS is defined according to the Rome III

---

**Figure 3** Principle by which probiotics can both provide benefits for diarrhea and constipation; normalization of the intestinal transit.

---

A recent epidemiological investigation found that 9.6% of hospital patients that were prescribed antibiotics developed AAD; mainly patients 65 years and older. The AAD incidence in ambulatory patients is less known. Nevertheless, AAD affects quality of life and causes a substantial cost to the health care system. Thus, complementary therapies that can reduce its incidence are certainly welcome.

The most common pathogens causing AAD are assumed to be *Clostridium difficile*, *Clostridium perfringens*, and *Staphylococcus aureus*. However, these pathogens do not account for all AAD and thus many unknown causes remain; some of which may be nonmicrobiological and relate to physiological changes in the host (eg, changed bile acid resorption).

Probiotics have been shown to be very successful in reducing risk for AAD.20 When looking at the settings, most studies have been performed in a clinical/hospital setting and have proved to be successful. Much less data are available on community settings and ambulatory patients.21 The use of probiotics has been calculated to reduce cost for diarrhea treatment by 25%;22 this is associated with a number needed to treat of 13.

In general, probiotic combinations, such as *Bifidobacterium bifidum* W23 + *B. lactis* W18 + *B. longum* W51 + *Enterococcus faecium* W54 + *Lactobacillus acidophilus* W37 + *L. acidophilus* W55 + *Lactobacillus paracasei* W72 + *Lactobacillus plantarum* W62 + *Lactobacillus rhamnosus* W71 + *Lactobacillus salivarius* W243 or *L. acidophilus* NCFM + *L. paracasei* Lpc-37 + *B. lactis* Bi-07 + *B. lactis* BL-043 or *L. acidophilus* CL1285 and *Lactobacillus casei* LBC80R35 have been shown to be successful. Among the single strains, *L. rhamnosus* GG has been shown to help;26 *E. faecium* SF68 has shown varying results.27 Also yeasts, in particular *Saccharomyces boulardii* (nom. inval.), have been reported to be efficacious in reducing AAD risk.20 The challenge here is that until recently no strain designations were reported in *S. boulardii*. The most common pathogens causing AAD are assumed to

---

A recent epidemiological investigation found that 9.6% of hospital patients that were prescribed antibiotics developed AAD; mainly patients 65 years and older. The AAD incidence in ambulatory patients is less known. Nevertheless, AAD affects quality of life and causes a substantial cost to the health care system. Thus, complementary therapies that can reduce its incidence are certainly welcome.

The most common pathogens causing AAD are assumed to be *Clostridium difficile*, *Clostridium perfringens*, and *Staphylococcus aureus*. However, these pathogens do not account for all AAD and thus many unknown causes remain; some of which may be nonmicrobiological and relate to physiological changes in the host (eg, changed bile acid resorption).

Probiotics have been shown to be very successful in reducing risk for AAD.20 When looking at the settings, most studies have been performed in a clinical/hospital setting and have proved to be successful. Much less data are available on community settings and ambulatory patients.21 The use of probiotics has been calculated to reduce cost for diarrhea treatment by 25%;22 this is associated with a number needed to treat of 13.

In general, probiotic combinations, such as *Bifidobacterium bifidum* W23 + *B. lactis* W18 + *B. longum* W51 + *Enterococcus faecium* W54 + *Lactobacillus acidophilus* W37 + *L. acidophilus* W55 + *Lactobacillus paracasei* W72 + *Lactobacillus plantarum* W62 + *Lactobacillus rhamnosus* W71 + *Lactobacillus salivarius* W243 or *L. acidophilus* NCFM + *L. paracasei* Lpc-37 + *B. lactis* Bi-07 + *B. lactis* BL-043 or *L. acidophilus* CL1285 and *Lactobacillus casei* LBC80R35 have been shown to be successful. Among the single strains, *L. rhamnosus* GG has been shown to help;26 *E. faecium* SF68 has shown varying results.27 Also yeasts, in particular *Saccharomyces boulardii* (nom. inval.), have been reported to be efficacious in reducing AAD risk.20 The challenge here is that until recently no strain designations were reported in *S. boulardii*. The most common pathogens causing AAD are assumed to
criteria as: recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with two or more of the following:
- Improvement with defecation
- Onset associated with a change in frequency of stool
- Onset associated with a change in form (appearance) of stool.

Furthermore, there is no evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the subject’s symptoms. IBS can be subtyped into diarrheal, constipation, or mixed type using the Bristol Stool Scale or may be undefined. As there is no clear etiology, treatment is challenging, even though IBS-like symptoms are among the most common reasons for visiting gastroenterologists. IBS appears to have a strong psychosomatic component and is therefore prone to a placebo effect; this necessitates that studies are sufficiently long (several months) and have sufficient numbers of volunteers (hundreds of people/treatment group). It may also be necessary to focus on one IBS subtype in order to have a sufficiently homogenous study population. Probiotics appear to have potential in relieving specific symptoms of IBS, such as abdominal pain (eg, VSL#3 or Bacillus coagulans GBI-30, 6086), bloating (eg, L. acidophilus NCFM + B. lactis Bi-07 or B. bifidum MIMBb75), and flatulence (eg, S. boulardii). Overall improvement in IBS quality of life, however, appears to be challenging. It is therefore also difficult to identify specific strains or strain combinations that would be most efficacious. However, as indicated earlier, selected strains have been documented to provide relief for selected symptoms of IBS.

**Necrotizing enterocolitis**

Necrotizing enterocolitis (NEC) is a very serious condition with a high mortality rate. The main risk group is very low birth weight infants (<1500 g). Fortunately, NEC is rare among live births in general (<0.1%). The pathogenesis of NEC is not fully understood, but likely to be multifactorial with an important microbial component. The intestinal microbiota of preterm infants has been reported to be less diverse than that of term infants and appears to be more commonly colonized by potential pathogenic species from genera such as Klebsiella, Enterobacter, and Clostridium. There is currently no treatment for the prevention of NEC. However, probiotics have been reported to be very successful in reducing NEC risk in the at-risk population and is actually one of the best documented benefits of probiotics. Because of the involvement of potential pathogens in the etiology of NEC, administration of probiotics should start as early as possible and continue until at least the corrected gestational age of 36 or 37 weeks.

Since most studies are relatively small and doses and study designs are varying, it is difficult to recommend specific strains for this application, on the other hand, it appears that most tested strain have been successful. This has led to the ever more widely accepted opinion that probiotics should be used routinely in the risk reduction of NEC. Despite this, the population is a very sensitive one that may suggest the need for more stringent quality control of the probiotic product; what this control should encompass in terms of microbiological safety testing remains to be determined. Furthermore, adverse events should be documented.

**Inflammatory bowel disease**

IBD can be divided into three different conditions: ulcerative colitis, which is an inflammatory condition limited to the colon; Crohn’s disease (CD), which is an inflammation that can be anywhere in the intestinal tract; and pouchitis, which is an inflammation of an ileal pouch.

IBD is characterized by periods of active disease, which is treated, and periods of remission. The etiology of IBD is not known, but the microbiota appears to play an important role. Hence, it is not surprising that probiotics have been considered for IBD. The main probiotics studied are Escherichia coli Nissle 1917 and the probiotic combination VSL#3. The former appears to be efficacious in maintaining remission in CD, while the latter appears to be efficacious in both inducing and maintaining remission in CD; for inducing remission in combination with conventional therapy and maintaining remission in ulcerative colitis; and maintaining remission in pouchitis.

**Helicobacter pylori eradication**

*Helicobacter pylori* is a common inhabitant of the gastric mucosa and has been found to be associated with gastric ulcer and gastric cancers. However, *H. pylori* has a dual role: exposure to the organism has been found to correlate with reduced risk for atopic dermatitis in children and eradication of *H. pylori* has been suggested to correlate with an increased risk of obesity. It is because of its pathogenic character that it is eradicated from carriers. While in vitro and animal studies have indicated antagonistic activities toward *H. pylori* by, in particular, *Lactobacillus* probiotics, this has not been replicated in humans. Probiotics can therefore not be considered as an alternative for standard therapy. Some strains such as *Lactobacillus johnsonii* La1 have been observed to reduce *H. pylori* numbers and activity, which may actually be preferable in light of the potential positive role the organism may play.
While not eradicating, probiotics have been found to be promising as adjuvants to standard therapy, reducing side effects, thereby improving compliance and leading to a higher success rate (72% vs 82%). This is also suggested in the Maastricht IV consensus report on treatment of H. pylori. The Maastricht IV report recommends (with recommendation grade D) the use of S. boulardii. The positive effect of certain probiotics in the eradication of H. pylori can be explained by similar mechanisms as for AAD risk reduction, though other factors seem to be involved as well.

Future
The continued in-depth analysis of the intestinal microbiota is likely to indicate new probiotic candidates. Comparison of microbiota between different populations not only indicates which organisms are positively associated with disease, but also which organisms are missing or reduced in numbers. Such organisms may have probiotic potential. Examples of this include Akkermansia muciniphila, a mucus degrading organism with anti-inflammatory potential that may play a role in reducing metabolic syndrome. Another example is Faecalibacterium prausnitzii, which also appears to have anti-inflammatory potential and maybe useful in CD.

Genetically modified probiotics have been tested already some time ago, such as IL-10 producing L. lactis strains and while successful this does not appear to have led to any greater success. Obviously, such probiotics are in the pharmaceutical range of the spectrum (Figure 2).

Conclusion
Digestive health is the “traditional” target for probiotics. Some health benefits seem to be fairly well established for a variety of strains, especially in infants and children, such as constipation/long transit, AAD, certain forms of community-acquired diarrhea, certain IBS symptoms, and NEC. With the exception of VSL#3 for IBD, it is not always easy to identify which strain (combination) is most efficacious. For the consumer, it therefore remains challenging to identify the appropriate product; some things to look for are numbers guaranteed until end of shelf life, and are strains indicated or just species and/or genus?

Disclosure
The author is an employee of DuPont Nutrition and Health. DuPont Nutrition and Health manufactures and commercializes probiotics. The author reports no other conflicts of interest in this work.

References
36. Hun L. Bacillus coagulans significantly improved abdominal pain and
35. Michail S, Kenche H. Gut microbiota is not modified by random
34. Drossman DA. Rome III: the new criteria.
33. Ouwehand AC. Probiotics for intestinal and respiratory health. NutraCos.
23. Koning CJ, Jonkers DM, Stobberingh EE, Mulder L, Rombouts FM,
22. Vandenplas Y, De Hert S; Probiotical Study Group. Cost/benefit of
181–185.
4. Michail S, Kercher H. Gut microbiota is not modified by randomized,
0. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A